ConcertAI, based in Cambridge, Massachusetts, announced that it entered into an agreement to acquire CancerLinQ, based in Alexandria, Virginia.
CancerLinQ is an oncology data platform developed by the American Society of Clinical Oncology, Inc. that collects and aggregates longitudinal electronic health record data from oncology practices throughout the United States. By using data from nearly 7 million patient records, CancerLinQ helps improve health outcomes for all oncology patients and advances evidence-based research.
ConcertAI is the leader in Real-World Evidence and Generative AI technology solutions for life sciences and health care. It works with biomedical innovators, health care providers and medical societies to accelerate outcomes for patients through AI and data. It serves more than 1,900 clinical sites and 45 biomedical innovators.
This acquisition will enhance and expand CancerLinQ’s use of real-world data, analytics, next-generation AI and other technologies to improve cancer care and speed clinical research. The financial terms of the acquisition were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 264th eHealth acquisition of 2023, and the 34th in the analytics specialty.
